Novartis' Advair knockoff nabs Belgian nod; Actelion could go head-to-head with Gilead hopeful; Merck KGaA inks deal in Mozambique;

@FiercePharma: AstraZeneca's stateside comeback for Brilinta has run aground on a DoJ investigation. Story | Follow @FiercePharma

@TracyStaton: Team effort here - The most influential people in biopharma today. Report | Follow @TracyStaton

@EricPFierce: Hospira CEO F. Michael Ball says the FDA has moved its Austin, TX and Rocky Mount, NC facilities to VAI status. | Follow @EricPFierce

@CarlyHFierce: Can't make an influentials list without Valeant CEO J. Michael Pearson - that M&A strategy has made waves. More | Follow @CarlyHFierce

> AirFluSal Forspiro, a generic version of Advair from Novartis' ($NVS) Sandoz unit, won approval for sale in Belgium for patients with asthma or chronic obstructive pulmonary disease. Report

> Actelion's new drug for pulmonary arterial hypertension, Opsumit, may face a head-to-head trial with Gilead Sciences' ($GILD) experimental treatment for the same condition. Report

> Germany-based Merck has teamed up with the government of Mozambique to train med students and others on treating diabetes and other chronic illnesses. Report

> Hikma Pharmaceuticals chose Said Darwazah, its CEO, to take on the role of chairman as well; non-executive Chairman Samih Darwazah is retiring. Report

> Pakistan's pharma industry fears a shortage of a number of drug products because of government red tape on active ingredients for narcotics. Report

> A U.S. judge blocked warrantless searches of an Oregon state database of prescription drug records. Report

Medical Device News

@FierceMedDev: Italian Dx outfit DiaSorin launched a new Rotavirus test in the EU - it could have legs in the developing world, too. Story | Follow @FierceMedDev

@MarkHFierce: Folks, we have a strong new issue of FierceDiagnostics ready for reading. News from Myriad, Brazil and more. Issue | Follow @MarkHFierce

@MichaelGFierce: Who are the most influential people in biopharma today? Check out FierceBiotech's 2014 list. Report | Follow @MichaelGFierce

@EmilyWFierce: King Richard III's genome to be sequenced by researchers at the University of Leicester. Article | Follow @EmilyWFierce

> FDA publishes its warning letter to Baxter over home dialysis and infusion devices. Story

> NC patients exposed to rare, fatal brain disease through dirty surgical tools. More

> Sequoia Capital leads $10M round for cancer Dx startup Guardant Health. Item

> The FDA hit Amgen with a warning over drug/device combo manufacturing violations. News

Biotech News

@FierceBiotech: As many as 5 life sciences companies could go public this week, bringing in a combined $115M. News | Follow @FierceBiotech

@JohnCFierce: Really enjoyed talking with One Nucleus members about biotech valuations. Interesting times. | Follow @JohnCFierce

@DamianFierce: The most influential people in biopharma today, according to FierceBiotech. Who'd we miss? Who doesn't belong? | Follow @DamianFierce

@EmilyMFierce: Penn cancer research Carl June made our list of most influential people in biopharma. Profile | Follow @EmilyMFierce

> Third Rock puts up $45M for a voyage into gene therapy. Story

> Aggressive Gilead considers head-to-head PAH showdown with Actelion. Article

Drug Delivery News

> CalTech: Antibody carriers grant HIV protection across mucosal membranes. More

> To fight muscular dystrophy, nanoparticles target cells that choke themselves with waste. Story

> BioDelivery looks for $60M offering to boost addiction film, pain gel. News

> Alnylam, MIT team develops RNA-delivering nanoparticles for the liver. Report

> Nasal vaccine delivery conquers West Nile Virus in fewer doses. Article

> Sonrgy grabs rights to UCSD-created ultrasound-nanocarrier tech. Item

Diagnostics News

> Guardant Health raises $10M and debuts a new blood Dx for personalized cancer treatment. Story

> One Brazilian Dx giant gets new majority shareholders, and another may be sold. News

> Scottish imaging agent startup raises a $6.56 million Series A round. More

> Myriad and Gene By Gene resolve their differences over BRCA cancer Dx tests. Article

> Exact will make its case on March 27 for FDA approval of a colon cancer Dx. Piece

> Alere improves Q4 numbers through revenue growth and cost cuts. Item

Pharma Marketing News

> Steering for a U.S. comeback, AstraZeneca's Brilinta runs aground on DoJ investigation. Story

> Will PBMs turn copay coupons into an endangered species? Article

> Big Pharma legal whiz sees DoJ, FDA crackdown on CEO quotes and press releases. Story

> Feds target Teva in probe of Copaxone, Azilect marketing. News

> Nestlé plans to use its global marketing juju to rev up Galderma. Article

> New NICE advice could put millions more U.K. patients on statins. Item

And Finally... A huge new study casts more doubt on the value of mammograms. Report

Suggested Articles

Belgian CDMO Ajinomoto Bio-Pharma Services has been on a run in recent of years expanding its operations around the world. That was the goal of an Ind

The company will commit $300 million over the next five years to hire more people of color and increase clinical trial diversity.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.